Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $15.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mitchell Kapoor has given his Buy rating due to a combination of factors related to Abeona Therapeutics’ promising product pipeline. The recent FDA acceptance of the Biologics License Application for ABO-102, a gene therapy for Sanfilippo syndrome type A, is a significant milestone. The therapy has received Priority Review status, with a decision expected by August 2025, and data from clinical trials shows a rapid and sustained decrease in heparan sulfate levels, alongside improvements in cognitive and communication abilities in patients.
Furthermore, the expected approval of Abeona’s lead candidate, prademagene zamikeracel (pz-cel), for treating recessive dystrophic epidermolysis bullosa (RDEB) by April 2025 strengthens the company’s position. The efficacy and durability of pz-cel, combined with its potential to outperform existing treatments due to a favorable efficacy profile, bolster the investment case for Abeona. These factors, along with the potential revenue streams from these therapies, underpin the Buy rating and the $15 price target set by Kapoor.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABEO in relation to earlier this year.